

LET US PRODUCE YOUR KNOW-HOW DRY POWDER INHALERS - AEROSOLS

GSK EVREUX IN MOTION



Phormaceutical site of Production of Inhaled Products







GSK EVREUX

A site recognized all over the world for micronisation and production of inhaled products. A multi-disciplinary team with broad experience to support your business needs from development to finished product supply, offering state-of-the-art technology and high process capabilities for your products.

DRY POWDER INHALERS PRODUCTION

Diskus[®] and Rotadisk[®] are devices containing multi dose medication to be inhaled. Dry Powder Inhalers are easy to use. Diskus[®] has a built in dose counter to help patients accurately taking their dose and indicate when a replacement is needed

AEROSOLS PRODUCTION

Each canister is comprised of a can and a valve.

The canister is filled under pressure with a predefined mixed quantity of active and propellant gas. Each can ster can be fitted with an actuator and a dose counter.

GSK EVREUX

GSK Worldwide

- GlaxoSmithKline one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
- We produce medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions.

In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

- More than 100 000 employees, all over the world, in 116 different countries.
- 78 manufacturing sites, based in 33 countries.
- 2009 turn over: 34,1 Billions euros.

GSK, in France

In 2009, GSK France is the third largest pharmaceutical group in France. For GSK, France, in terms of trade, is the first European subsidiary and the second subsidiary in the world, behind the United States.


Our locations:

Manufacturing Site
Headquarter
R&D Center
Manufacturing Site
Manufacturing Site
Biologicals Manufacturing Site



The Evreux site is dedicated to production of micronized and inhaled products. GSK Evreux employing over 1000 people, is manufacturing aerosols and dry powder inhalers for all markets. Our teams of experts and multi-skilled staff in respiratory processes (micronisation, filling, analytical, quality) are now available to support your challenges.

More than 500 Million of Ventolin HFA canisters have been supplied in the world over the last 10 years.



Marc Santesmases - Site Director

Key figures

Foundation	1968
Location	
Forms	Inhaled Aerosois Rotadisks® Diskus®
Distribution	120 customers including China, US, Japan
Sales breakdown	№ 15% Framoe№ 85% Export



Quality is our first priority

Quality is at the heart of all activities that support the development, manufacturing, supply and marketing of products to our patients and customers. It means doing what is right, first time every time.

Our Agreements:

Our excellent quality, regulatory status and compliance are endorsed by national and international following agreements for more than 20 years



- EMEA (Europe)
- FDA (US)
- MLHW (Japan)
- ANVISA (Brazil)
- MoH (Iran, Saudi Arabia, Yemen, Ouganda)
- SFDA (China)











A specific knowledge in inhaled products quality control

We have comprehensive laboratory facilities to support quality, product development, engineering, and physical properties analysis with state-of-the-art instrumentation.




Inhaled analytical expertise

Quality control analysts have developed a recognized experiese in respiratory physical and chemical analysis, for more than 40 years.

This expertise is also covering, analytical method development, stability studies, and specific respiratory equipments development.

4 - SERVICE'S GSK EVREUX



Operational Excellence

We have a culture of continuous improvement coupled with operational excellence and lean sigma. We are committed to removing waste and complexity from our operations.

A highly skilled site

Staff and Training

- · High level of qualifications and training
- 50% are graduated from higher education or master
- Partnerships developed with universities (Engineers, Pharmacists, ...)
- Continuous investment in people development

A site committed to the environment

Health, Safety and Environment

Reducing our impact on the environment is one of our priority through continuous improvement programs:

- Carbon foot print and COV reduction
- · Water zero reject
- Waste reduction and recycling
- Energy consumption reduction

Our main equipments (micronizers, blenders and filling equipments) are Respiratory Free designed.

The site is certified OHSAS 18 001 and plans ISO 14001.

All Environmental, Health and Safety team have been trained and certified to conduct EHS audits (COV, carbon footprint assessment, certifications support, Zero access, Ergomotricity).





















Active Pharmaceutical Ingredient

GSK Evreux is in charge of Active Ingredient micronisation for all the other production sites. This process requires state-of-the-art technology and specific knowledge.

Aerosols

From filling to packaging, a fully dedicated area for aerosols manufacturing compliant with the highest worldwide regulatory expectations

Dry Powder Inhalers (DPI)

State-of-the-art technology are used to manufacture pharmaceutical dry powder inhalers

Development

A multi disciplinary team including representatives from quality, engineering, medical device design, process experts operations and regulatory affairs available for your business.